9 citations
,
October 2020 in “Journal of The American Academy of Dermatology” This letter discusses the limited adaptation of low dose oral minoxidil for androgenetic alopecia in North America and reports no new clinical results; the authors suggest safety concerns or unclear dosing may be factors.
7 citations
,
November 2023 in “JAAD Case Reports” This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.
7 citations
,
September 2013 in “Current Dermatology Reports” This review summarizes existing literature on the safety of commonly used dermatologic medications during pregnancy but does not present new clinical findings, aiming to assist physicians with prescribing decisions.
4 citations
,
January 2022 in “Open Health” This article discusses the challenges in treating PCOS, highlights the role of lifestyle interventions, and notes the lack of effective treatment beyond symptomatic management for this common reproductive health issue.
4 citations
,
May 2002 in “Dermatologic Surgery” This article describes a technique for evaluating and treating the under-addressed temporal peak areas in hair restoration surgery to improve cosmetic harmony with the frontal hairline.
3 citations
,
August 2025 in “Frontiers in Pharmacology” Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
2 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” This study suggests that Janus kinase inhibitors may offer a potential treatment option for refractory lichen planopilaris and frontal fibrosing alopecia, showing positive response rates between 42% and 100%, though evidence quality is low.
2 citations
,
January 2021 in “Journal of The American Academy of Dermatology” This commentary highlights the consistency of recent findings on low-dose oral minoxidil's tolerability for androgenetic alopecia, noting infrequent side effects except for hypertrichosis.
1 citations
,
January 2026 in “Journal of Pharmaceutical Analysis” This review highlights the potential of natural compounds like terpenoids, flavonoids, and polyphenols in promoting hair regrowth for those with alopecia areata by activating growth pathways and modulating immune responses, but calls for further research to confirm their therapeutic utility.
1 citations
,
April 2023 in “Heliyon” In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.
1 citations
,
March 2018 in “Hair transplant forum international” This article reviews regenerative therapy for treating various types of hair loss and does not present new clinical findings.
1 citations
,
June 2008 in “中医杂志:英文版” This essay introduces Dr. Qiu's approach to treating consumptive syndromes with TCM after radio-chemotherapy, discussing how modern cancer treatments cause these symptoms and his unique perspective on their management.
June 2026 in “Health Science Reports” This review proposes a theoretical model for treating androgenetic alopecia using STEAP3 protein, based on recent findings about genetic mutations affecting molecular pathways, but emphasizes that this hypothesis needs validation through laboratory and clinical studies.
February 2026 in “Frontiers in Immunology” In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.
January 2026 in “Biomacromolecules” This study reports that a novel nanolipogel with moderate rigidity (NLG-2.5) enhances transdermal delivery of fucosterol, displaying superior permeability, targeting hair follicles, and promoting hair growth in androgenetic alopecia model mice by inhibiting inflammation and androgen pathways and promoting angiogenesis.
January 2026 in “International Journal of Health Science” In this pilot study, patients with atrophic acne scars experienced clinical improvements and high satisfaction after receiving three biweekly microinfusions of human insulin into their skin.
This study reviews the potential of rosemary extract for promoting hair growth and reducing hair fall, noting that its efficacy is comparable to minoxidil and that it is generally safe for topical use, though further clinical trials are needed to standardize formulations and dosages.
October 2025 in “Pielegniarstwo XXI wieku / Nursing in the 21st Century” This review discusses the effectiveness and mechanisms of combined oral contraceptives in treating acne vulgaris but reports no new clinical results; the authors highlight their antiandrogenic effects for managing acne and related endocrine disorders.
September 2025 in “Modern medical technology” This study reports that hair transplantation using follicular unit extraction and direct hair implantation can effectively restore scalp hair in post-burn alopecia, achieving natural hair direction and satisfactory growth density.
July 2025 in “Pharmaceutics” This review discusses the application of transdermal drug delivery systems for androgenetic alopecia and explores new technologies to enhance drug penetration but reports no clinical results.
July 2025 in “Dermatology Reports” This review indicates that mesenchymal stem cell therapy may offer clinical improvements for immune-mediated inflammatory skin diseases, showing promise particularly for those unresponsive to traditional treatments, but emphasizes the need for larger, controlled trials to confirm these results.
June 2025 in “Journal of Cosmetic Dermatology” This study reports that autologous micrografting may effectively treat stretch marks by promoting extracellular matrix remodeling and enhancing fibroblast activity, potentially expanding therapeutic options for this condition.
June 2025 in “World Journal of Medical Oncology” In this study, researchers explored the use of new biobased compounds and gels as potential treatments for skin cancer, finding that these biological materials may be significant in limiting and eliminating skin tumors alone or when combined with other methods.
March 2025 in “Human Movement” This review summarizes the role of platelet-rich plasma in treating musculoskeletal injuries in athletes, highlighting its current and potential applications, but it reports no new clinical findings.
This review concludes that platelet-rich plasma is a promising treatment for androgenetic alopecia, enhancing hair density and thickness, though outcomes vary due to differences in preparation and application methods.
This source reports that an international panel of dermatologists has provided a consensus statement to guide clinicians on the off-label use of low-dose oral minoxidil for treating hair loss.
December 2024 in “Journal of Contemporary Medical Practice” This paper examines six famous traditional Chinese medicine prescriptions, exploring their use in treating alopecia based on Zhang Zhongjing's texts, and aims to provide new clinical treatment ideas for hair loss.
August 2024 in “Journal of Contemporary Medical Practice” In this analysis, Professor Ma Shuanquan attributes androgenetic alopecia to liver, spleen, and kidney dysfunctions and describes a treatment approach using Chinese medicines focused on these organs, suggesting individualization and noting significant therapeutic effects.
August 2024 in “Skin Research and Technology” In this systematic review and meta-analysis, PRP therapy significantly improved hair density and thickness for women experiencing hair loss, with mild and transient adverse effects, suggesting potential tailored treatment protocols based on dosage, injection duration, and ethnicity.
July 2024 in “Medical alphabet” This review article explores the pathogenesis of vitiligo and examines various therapeutic approaches, specifically highlighting the potential use of oral and topical Janus kinase inhibitors for treatment.